The in vivo quantification of receptor concentration and ligand affinity, using data obtained with positron emission tomography, is based on a compartmental analysis of the ligand-receptor interactions. To investigate the affinity of drugs for the receptor sites and/or the possible alterations in various diseases of the receptor concentrations or of the drug interactions, many methods for quantitatively measuring the binding parameters have been devised.
SyrotaAPaillotinGDavyJMAumontMC. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci.1984;35: 937–945.
2.
PerlmutterJSLarsonKBRaichleMEMarkhamJMintunMAKilbournMRWelchMJ. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab.1986;6:154–169.
3.
WongDKGjeddeAWagnerHN. Quantification of neuroreceptors in the living human brain, I, Irreversible binding of ligands. J Cereb Blood Flow Metab.1986;6:137–146.
4.
DelforgeJJanierMSyrotaACrouzelCValloisJMCaylaJLanconJPMazoyerBM. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation.1990;82:1494–1504.
5.
DelforgeJSyrotaAMazoyerB. Experimental design optimization: Theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys Med Biol.1989; 34:419–435.
6.
FardeLHallHEhrinESedvallG. Quantitative analysis of D2 dopamine receptor binding in the living brain by PET. Science.1986;231:258–261.
7.
MintunMARaichleMEKilbournMRWootenGFWelchMJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol.1984;15:217–227.
8.
DelforgeJBendriemBSyrotaA. The concept of reaction volume in the in vivo ligand-receptor model. J Nucl Med.1996;37:118–125.
9.
DelforgeJSyrotaABottlaenderMVarastetMLoc'hCBendriemBCrouzelCBrouilletEMazièreM. Modeling analysis of [11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cereb Blood Flow Metab.1993;13:454–468.
10.
DelforgeJLoc'hCHantrayeOStulzaftOVarastetMMazièreMSyrotaAMazièreB. Kinetics analysis of central 76Br-Bromolisuride binding to dopamine D2 receptors studied by PET. J Cereb Blood Flow Metab.1991;11:914–925.
11.
HuangSHBarrioJBPhelpsME. Neuroreceptor assay with positron emission tomography: Equilibrium versus dynamic approaches. J Cereb Blood Flow Metab.1986;6:515–521.
12.
KesslerRMAnsariMSDe PaulisTSchmidtDEClantonJASmithHEManningRGGillespieDEbertMH. High affinity dopamine D2 receptor radioligands. Regional rat brain distribution of Iodinated benzamides. J Nucl Med.1991;32:1593–1600.
13.
FrostJJWagnerHN. Kinetics of binding to opiate receptors in vivo predicted from the in vitro parameters. Brain Research.1984;305:1–11.
14.
KoeppeRAHolthoffAFreyKAKilbournMRKuhlDE. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab.1991; 11:735–744.
15.
PatlakCSBlasbergRGFenstermacherJD. Graphical evaluation of blood-to-brain transfer constant from multiple-time uptake data. J Cereb Blood Flow Metab.1983;3:1–7.
16.
DelforgeJLe GuludecDSyrotaABendriemBCrouzelCSlamaMMerletM. Quantification of myocardial muscarinic receptors with PET in humans. J Nucl Med.1993;34:981–991.
17.
DelforgeJPappataSMilletPSamsonYBendriemBJobertACrouzelCSyrotaA. Modeling analysis of [11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cereb Blood Flow Metab.1995;13:454–468.
18.
DelforgeJSyrotaALanconJPNakajimaKLoc'hCJanierMValloisJMCaylaJCrouzelC. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177 and a new graphical method. J Nucl Med.1991;32:739–748.
19.
Le GuludecDDelforgeJSyrotaADesruennesMValetteHGandjbakhchIMerletP. In vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation.1994;99:172–178.
20.
MerletPDelforgeJSyrotaAAngevinEMazièreBCrouzelCValetteHLoisanceDCastaigneEDubois-RandeJL. Positron emission tomography with C11-CGP 12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation.1993;87:1169–1178.
21.
PappataSSamsonYChavoisCPrenantCMazièreMBaronJC. Regional specific binding of [11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow Metab.1988;8:304–313.
22.
SavicIPerssonARolandPPauliSSedvallGWidenL. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet.1988;2:863–866.
23.
AbadiePBaronJCBisserbeJCBoulengerJPRiouxPTravereJMBarréLPetit-TabouéMCZarifianE. Central benzodiazepine receptors in human brain: Estimation of regional B'max and Kd values with positron emission tomography. Eur J Pharmacol.1992;213:107–115.
24.
BlomqvistGPauliSFardeLErikssonLPerssonAHalldinC. Maps of receptor binding parameters in the human brain—A kinetic analysis of PET measurements. Eur J Nucl Med.1990;16:257–265.
25.
DelforgeJSpelleLBendriemBSamsonYBottlaenderMPapageorgiouSSyrotaA. Quantitation of the benzodiazepine receptor in human brain using a partial-saturation method. Nucl Med.1996b;37: 5–11.
26.
LassenNBartensteinPLammertsmaAPrevettMTurtonDLuthraSOsmanSBloomfieldPJonesTPatsalosPO'ConnellMDuncanJVanggaardAndersen J. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab.1995;15:152–165.
27.
MilletPDelforgeJMauguièreFPappataSCinottiLFrouinVSamsonYBendriemBSyrotaA. Parametric images of benzodiazepine receptor concentration in human brain: Comparison with the distribution volume approach. J Nucl Med.1995;36: 1462–1471.
